Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trialPhoto Teclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma Used in Teclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma en
Teclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma